Ka Hin Tai

Ka Hin Tai

Auto-generated profile, based on publicly available information

Ka Hin Tai

Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), UMR_S 1085, F-35000 Rennes, France

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2025 in Journal of Clinical Epidemiology
Verified
Journal Article
Open access
KTKa Hin Tai
Ka Hin Tai
MMMarcel Benjamin Mueller
Marcel Benjamin Mueller
UMUlrich Mansmann
Ulrich Mansmann
AAAnna Catharina Vieira Armond
Anna Catharina Vieira Armond
EDEvelyne Decullier
Evelyne Decullier
USUlrich Sax
Ulrich Sax
The Findable, Accessible, Interoperable, and Reusable guiding principles promote Findability, Accessibility, Interoperability, and Reuse of data to enhance data management and stewardship. In biomedicine, particular ethical, legal, and technical barriers complicate research data sharing. To help researchers overcome these challenges, we propose a framework of FAIRification from three dimensions - scientific, technical, and legal/ethical. We advocate for prospective FAIRification of study data, starting with a strong emphasis on planning for data-sharing from the beginning. Reflective questions throughout the process guide researchers to reflect on their situation. Researchers should assess resources and feasibility, secure technical and legal support, consider stakeholder needs, and devise an appropriate data sharing process. Given the sensitivity of biomedical data, confidentiality and security require careful attention. The data sharing strategy should be finalized before the study starts and documented in relevant study materials. Technical preparation for data sharing follows planning. Data should be well-documented with a data dictionary and metadata to facilitate reuse and provided in an accessible format. The data can be hosted on a repository to promote sharing and reuse. While a secure repository provides the technical foundation for data protection, effective administration is required to enforce data use agreements and licensing. We also discuss the importance of subsequent management upon data upload. Continued support for researchers and data maintenance are essential for effective reuse. Examples and resources to facilitate FAIRification are included to help researchers navigate challenges and ensure biomedical data are FAIR and reusable.

10 August 2026 in Journal of Clinical Epidemiology
Verified
Journal Article
Open access
KTKa Hin Tai
Ka Hin Tai
GVGiulia Varvarà
Giulia Varvarà
EEEmma Escoffier
Emma Escoffier
UMUlrich Mansmann
Ulrich Mansmann
NDNicholas J. DeVito
Nicholas J. DeVito
FNFlorian Naudet
Florian Naudet

25 March 2026 in Trials
Verified
Journal Article
Open access
PDF file
CBCora Burgwinkel
Cora Burgwinkel
HCHan Chang Chiam
Han Chang Chiam
KTKa Hin Tai
Ka Hin Tai
JWJifan Wang
Jifan Wang
MAMian Haider Ali
Mian Haider Ali
LHLeonhard Held
Leonhard Held
Background: Reproducing published findings from clinical trials is a critical component of scientific transparency, yet it remains a challenging and under-practiced task. Despite increasing emphasis on reproducibility and data reuse in research policies, only few real-world examples exist where several teams have reproduced complex analyses using clinical trial data. In this case study, the aim was to reproduce the key findings of a high-impact clinical trial on rectal cancer treatment using shared trial data. Method: We organized a multi-team datathon, where each team was provided with the same dataset and supporting material, and was tasked to reproduce the results of the CAO/ARO/AIO-04 trial, with optional additional analyses. We contacted the original investigators for access and reuse of the data, as well as information on the clinical and scientific aspects of the study. Results: Five teams used R or Python to reproduce the statistical results, and the corresponding scripts can be found on Gitlab. The key findings on disease-free survival (DFS) were consistently reproduced by most teams, reinforcing confidence in the main trial conclusions. Result robustness was investigated using different analytical software or statistical models. Some challenges were encountered because supplementary material of the original study was not easily found. Minor reporting issues were also identified in the reproduced paper. Conclusions: Reproduction of a major oncology clinical trial confirmed the reliability of its main conclusions. Divergences highlighted reporting gaps—such as incomplete protocols and broken links—that future trials should address. This case study demonstrates the value of systematic reproducibility checks for the transparency of clinical research and the challenges in data sharing for reproducibility.

15 October 2025 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
KTKa Hin Tai
Ka Hin Tai
GLGérard Legoff
Gérard Legoff
ALAnne Le Louarn
Anne Le Louarn
NMNchangwi Syntia Munung
Nchangwi Syntia Munung
FNFlorian Naudet
Florian Naudet
Open science often centers around publications and data transparency. We highlight how and why disseminating results to study participants is essential for maximizing the values and benefits of open science.

7 November 2025 in medRxiv
Verified
Preprint
Open access
PDF file
CBCora Burgwinkel
Cora Burgwinkel
HCHan Chang Chiam
Han Chang Chiam
KTKa Hin Tai
Ka Hin Tai
JWJifan Wang
Jifan Wang
MAMian Haider Ali
Mian Haider Ali
LHLeonhard Held
Leonhard Held
Background: Reproducing published findings from clinical trials is a critical component of scientific transparency, yet it remains a challenging and under-practiced task. Despite increasing emphasis on reproducibility and data reuse in research policies, few real-world examples exist where independent teams have reproduced complex analyses using clinical trial data. In this case study, the aim was to independently reproduce the key findings of a high-impact clinical trial on rectal cancer treatment using shared trial data. Method: We organized a multi-team datathon, where each team was provided with the same dataset and supporting material, and was tasked to reproduce the results of the CAO/ARO/AIO-04 trial, with optional additional analysis. We contacted the original investigators for data access and reuse, and consulted them to understand the study, clinically and scientifically. Results: Five teams used R or Python to reproduce the statistical results, and the corresponding scripts can be found on Gitlab. All teams reproduced the analyses for primary outcome disease-free survival (DFS). The key findings on DFS were consistently reproduced, reinforcing confidence in the trial main conclusions. Result robustness was investigated using a different analytical software or statistical models. Nevertheless, challenges were encountered when the supplementary materials were not easily identified. Minor reporting issues were noticed in the reproduced paper. Conclusion: Reproduction of a major oncology clinical trial confirmed the reliability of its main conclusions. Divergences highlighted reporting gaps, such as incomplete protocols and broken links, that future trials should address. This case study demonstrates the value of systematic reproducibility checks for clinical research transparency and challenges in data sharing for reproducibility.

22 October 2026 in BMC Medicine
Verified
Journal Article
Open access
PDF file
UMUlrich Mansmann
Ulrich Mansmann
KTKa Hin Tai
Ka Hin Tai
GVGiulia Varvarà
Giulia Varvarà
FNFlorian Naudet
Florian Naudet
Background: Clinical trial data sharing is increasingly endorsed by journals, funders, regulators, and research organisations. Nevertheless, access to individual participant data (IPD) remains inconsistent and may not be available when trial results are published. Access timelines can reflect several distinct components, including scientific and governance review, contractual and legal procedures, data preparation, de-identification, transfer, and subsequent harmonisation. When original data are unavailable, researchers may reconstruct approximate participant-level event-time data from published Kaplan-Meier curves. Trinquart and Stockler recently proposed that trialists instead release minimal analysable time-to-event data at publication. Their proposal raises a broader question: what kinds of data and documentation are required for different forms of reproducibility and scientific reuse? Main text: We argue that clinical trial data transparency should be considered in relation to the scientific claims and research activities that a particular data object can support. We propose a three-tier framework for data intentionally released or made accessible by trialists or data custodians. Tier 1 comprises original publication-time reduced datasets and supports endpoint-level numerical reproducibility and analyses that are functions of the released observations. Tier 2 comprises reproducibility packages containing analysis-ready data, code, derivation logic, and documentation sufficient to reproduce the reported analytic process. Tier 3 provides governed access to broader de-identified IPD for substantively new analyses and reassessment of operational and analytic decisions. Reconstructed pseudo-IPD are considered separately because they are generated externally from publications rather than shared from the trial database. Privacy protection, governance, and processing environment are cross-cutting dimensions and do not map uniquely to a particular tier. They also apply differently to each tier. Conclusions: Publication-time reduced datasets can provide meaningful and timely transparency when broader IPD are not yet accessible. Their value should be recognised without confusing endpoint-level numerical reproducibility with reproduction of the complete analytic process or broader scientific reuse. We propose that publication-time reduced datasets should form a practical floor for timely transparency, while reproducibility packages and governed access to broader IPD provide progressively richer opportunities for reproducing, interrogating, and extending clinical trial analyses.